This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Vyndaqel 61mg is indicated for the treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy
(ATTR-CM).1
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SmPC for how to report adverse reactions.
As early as 1 month, patients with ATTR-CM treated with VYNDAQEL (tafamidis meglumine) 80 mg demonstrated significantly greater TTR stabilization vs placebo (87.8% vs 3.5%), respectively; p<0.0001)2
As early as 6 months, VYNDAQEL demonstrated a significant reduction in decline in functional capacity (6MWT) vs placebo1
As early as 6 months, VYNDAQEL demonstrated a significant reduction in decline of quality of life (KCCQ-OS) vs placebo1
At first measurement, patients receiving VYNDAQEL showed smaller increases in NT-proBNP levels vs those receiving placebo (at 12 months)1
Legal Category: S1A.Further information available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023